Can-Fite BioPharma Ltd. (TLV:CANF)
Israel · Delayed Price · Currency is ILS · Price in ILA 484.60
+26.10 (5.69%)
Apr 24, 2026, 1:44 PM IDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
258.23K ILS
Profits / Employee
-6.27M ILS
Market Cap
20.77M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Bonus BioGroup | 37 |
| BioLineRx | 24 |
| Matricelf | 15 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| Geffen Residence & Renewal | 6 |
| BioLight Life Sciences | 4 |
Can-Fite BioPharma News
- 25 days ago - Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs - GuruFocus
- 25 days ago - Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - GlobeNewsWire
- 4 weeks ago - Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - GlobeNewsWire
- 5 weeks ago - Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment - GuruFocus
- 5 weeks ago - Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - GlobeNewsWire
- 7 weeks ago - Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants - Nasdaq
- 7 weeks ago - Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study - Benzinga
- 7 weeks ago - Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study - GuruFocus